Colestilan chloride
BindRen (colestilan chloride) is a small molecule pharmaceutical. Colestilan chloride was first approved as Bindren on 2013-01-21. It has been approved in Europe to treat hyperphosphatemia.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
V: Various drug classes in atc
V03: All other therapeutic products
V03A: All other therapeutic products
V03AE: Drugs for treatment of hyperkalemia and hyperphosphatemia
V03AE06: Colestilan
HCPCS
No data
Clinical
Clinical Trials
13 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Chronic renal insufficiencyD051436N1811011
Kidney diseasesD007674EFO_0003086N0811011
HyperphosphatemiaD0545591910
DialysisD00395677
DyslipidemiasD05017122
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type 2 diabetes mellitusD003924EFO_0001360E1111
Diabetes mellitusD003920EFO_0000400E08-E1311
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypercholesterolemiaD00693711
Alzheimer diseaseD000544EFO_0000249F0311
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameColestilan chloride
INNcolestilan
Description
BindRen (colestilan chloride) is a small molecule pharmaceutical. Colestilan chloride was first approved as Bindren on 2013-01-21. It has been approved in Europe to treat hyperphosphatemia.
Classification
Small molecule
Drug class
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Identifiers
PDB
CAS-ID95522-45-5
RxCUI
ChEMBL IDCHEMBL2103800
ChEBI ID
PubChem CID
DrugBank
UNII IDVSI302RYSR (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
25 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use